biostudies-literatureWu BRTaiwan Ministry of Health and Welfare Clinical Trial CenterTseng-Lien Lin Foundation,MOST Clinical Trial Consortium for Stroke5626https://www.ebi.ac.uk/biostudies/studies/S-EPMC9571401biostudies-literatureUnknown11(19)Statins exert cholesterol-independent beneficial effects, including immunomodulatory effects. In this study, we attempted to investigate the association between statin therapy and the risk of viral infection. We conducted a retrospective cohort study using data from Taiwan's National Health Insurance Research Database. We identified patients with hyperlipidemia and divided them into two cohorts: statin users and statin nonusers. A 1:1 propensity score matching was conducted between the two cohorts, and a Cox proportional hazards model was used to evaluate the risk of viral infection. Overall, a total of 20,202 patients were included in each cohort. The median follow-up durations were 4.41 and 6.90 years for statin nonusers and users, respectively. The risk of viral infection was 0.40-fold Journal of clinical medicineStatin Therapy and the Risk of Viral Infection: A Retrospective Population-Based Cohort Study.PMC9571401MOST 109-2321-B-039-002MOHW109-TDU-B-212-114004Taichung, TaiwanLiao WCYin MCChou CHLin CLPeng YHHo WCWu BRChen DHfalseStatin Therapy and the Risk of Viral Infection: A Retrospective Population-Based Cohort Study.Statins exert cholesterol-independent beneficial effects, including immunomodulatory effects. In this study, we attempted to investigate the association between statin therapy and the risk of viral infection. We conducted a retrospective cohort study using data from Taiwan's National Health Insurance Research Database. We identified patients with hyperlipidemia and divided them into two cohorts: statin users and statin nonusers. A 1:1 propensity score matching was conducted between the two cohorts, and a Cox proportional hazards model was used to evaluate the risk of viral infection. Overall, a total of 20,202 patients were included in each cohort. The median follow-up durations were 4.41 and 6.90 years for statin nonusers and users, respectively. The risk of viral infection was 0.40-fold 2022-01-01T00:00:00Z2022 Sep2025-05-29T21:27:24.79Z2025-05-29T21:27:24.79ZS-EPMC95714013623349310.3390/jcm11195626